Aquavit

Meet Big Thirst, the Distilled Spirits Industry's Most Comprehensive E-commerce Sales and Marketing Engine

Retrieved on: 
Wednesday, October 6, 2021
People, Public relations, Compliance, Breast cancer, Aquavit, ROI, Sale, Big data, Marketing, CEO, Noise, Growth, Thirst, Awareness, Technology, Intelligence, Breast Cancer Awareness Month, Time, Industry, Online shopping, Retail

The time is right for a new e-commerce company to make online sales more effective for spirits brands.

Key Points: 
  • The time is right for a new e-commerce company to make online sales more effective for spirits brands.
  • "We are excited to help distilleries and spirits brands expand their market reach faster and easier with online sales," says Matt McGinnis, CEO of Big Thirst.
  • While Big Thirst is an e-commerce start up, it is founded by passionate beverage industry veterans and is powered by a distribution and sales consultancy, Big Thirst Consulting , and a full-service marketing agency, Big Thirst Marketing .
  • Big Thirst is a full-service sales and marketing engine powered by a compliance, distribution and sales consultancy, Big Thirst Consulting, and a full-service marketing agency, Big Thirst Marketing.

Aquavit's AQV-1122 COVID-19 Vaccine Patent Approval Fast Tracked by USPTO

Retrieved on: 
Wednesday, September 1, 2021
LCS, B cell, Infection, Epidermis, Technology, Aquavit, COVID-19, Efficiency, Health, Multimedia, Public health, APC, PEPP, Safety, Patient, Compliance, Patent, View, USPTO, Pharmaceutical industry, Vaccine

"Globally there has been a surge in interest in skin vaccinations; as the demand for higher immune responses and better patient compliance continues to increase.

Key Points: 
  • "Globally there has been a surge in interest in skin vaccinations; as the demand for higher immune responses and better patient compliance continues to increase.
  • We are extremely pleased to introduce AQV-1122 into our rapidly expanding intellectual property portfolio.
  • The patent addresses platform technologies directed toward innovative methods for immunizing patients against infectious diseases using microchannel technologies.
  • Our technology is not only minimally invasive, but it also facilitates a more effective immune response than traditional syringe injections.

Patent Granted to Aquavit for Novel RoA and MoA for Bioactive Compositions

Retrieved on: 
Tuesday, May 4, 2021
Intangible assets, Aquavit, Patent, Pharmaceutical industry, United States patent law

b'NEW YORK, May 4, 2021 /PRNewswire/ -- U.S. patent number 10,980,865 [Application Number 14/909,954] was granted to Aquavit Pharmaceuticals, Inc. for direct application system and method for the delivery of bioactive compositions and formulations.

Key Points: 
  • b'NEW YORK, May 4, 2021 /PRNewswire/ -- U.S. patent number 10,980,865 [Application Number 14/909,954] was granted to Aquavit Pharmaceuticals, Inc. for direct application system and method for the delivery of bioactive compositions and formulations.
  • "It has taken many years to get this patent granted.
  • As a plastic surgeon and medical innovator, I am proud of the advances we have made with Aquavit."
  • "Under the leadership of Sobin Chang, Aquavit continues to push the envelope in the aesthetic space - bridging technology and medical treatments.

Aquavit Wins a Trademark Case over AQUAGOLD in European Union Intellectual Property Office Against a Counterfeiter

Retrieved on: 
Thursday, April 15, 2021
European Union trademark law, Intellectual property law, Brand management, Product management, Intellectual property organizations, Trademark, Marketing, European Union trade mark, European Union Intellectual Property Office, Aquavit, European Union

b'NEW YORK, April 15, 2021 /PRNewswire/ --The European Union Intellectual Property Office (EUIPO) declared that U-BioMed\'s falsely registered AQUAGOLD European Union trademark (No.

Key Points: 
  • b'NEW YORK, April 15, 2021 /PRNewswire/ --The European Union Intellectual Property Office (EUIPO) declared that U-BioMed\'s falsely registered AQUAGOLD European Union trademark (No.
  • 17902149) is invalid in its entirety, as it was originally created and owned by Aquavit Pharmaceuticals, Inc. ("Aquavit").
  • The division concluded that "the [Aquavit\'s] application was totally successful and U-BioMed\'s European Union trademark has been declared invalid for all the contested goods.
  • "\nAquavit\'s microchannel technology, AQUAGOLD, was launched in 2014 at the American Academy of Dermatology, the largest dermatology conference in the world.

European Union Intellectual Property Office Revokes Counterfeiter's Fake AQUAGOLD® Design Registration and Orders Payment to Aquavit of All Legal Fees and Costs

Retrieved on: 
Thursday, December 10, 2020
Aquavit, AAD, American Academy of Dermatology

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") received a decision from the European Union Intellectual Property Office (EUIPO) today that it has revoked the counterfeiter U-BioMed's falsely registered AQUAGOLD design, originally created and owned by Aquavit.

Key Points: 
  • NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") received a decision from the European Union Intellectual Property Office (EUIPO) today that it has revoked the counterfeiter U-BioMed's falsely registered AQUAGOLD design, originally created and owned by Aquavit.
  • Aquavit introduced AQUAGOLD fine touch at the American Academy of Dermatology (AAD) in 2014 and has been praised globally by doctors, patients, key opinion leaders, and the media.
  • AAD is the largest dermatology conference in the world, attended by tens of thousands of doctors and healthcare professionals from around the world.
  • Following the success, counterfeiters have been copying the brand logo and design to sell fake AQUAGOLD medical devices to everyone, everywhere possible.

Aqua ViTea Survey Shows Consumers Would Rather Ditch Alcohol for a Month Than Give Up Food Delivery Services

Retrieved on: 
Wednesday, December 9, 2020
Fermented drinks, Branches of biology, Drinking culture, Food, Kombucha, Mycology, Drinks, Aquavit, Alcoholic drink, Biology

For those taking a break from booze, a recent survey commissioned by Aqua ViTea found that the health-packed elixir, kombucha, is the alcohol alternative drink of choice for 44% of respondents.

Key Points: 
  • For those taking a break from booze, a recent survey commissioned by Aqua ViTea found that the health-packed elixir, kombucha, is the alcohol alternative drink of choice for 44% of respondents.
  • Aqua ViTea's survey revealed the following:
    When asked whether they would rather give up food delivery services or alcohol, a staggering 65% of respondents would much prefer to give up hard beverages.
  • "Offering consumers healthier beverage options is what motivated me to start Aqua ViTea, and I'm excited to continue this mission in 2021.
  • For more information on Aqua ViTea, or to find a retailer near you visit https://www.aquavitea.com/ or like Aqua ViTea on Facebook at https://www.facebook.com/AquaVitea/ and follow the brand on Instagram @aquaviteakombucha.

Aquavit Pharmaceuticals, Inc. Wins Default Judgement Against Counterfeiter

Retrieved on: 
Tuesday, September 8, 2020
Pharmaceuticals policy, Aquavit, Pharmaceutical industry in China, Trademark infringement

NEW YORK, Sept. 8, 2020 /PRNewswire/ --Aquavit Pharmaceuticals, Inc. ("Aquavit") won a default judgement against counterfeiter in the United States District Court for the Southern District of New York in a civil action against Global Medi Products, a South Korean company.

Key Points: 
  • NEW YORK, Sept. 8, 2020 /PRNewswire/ --Aquavit Pharmaceuticals, Inc. ("Aquavit") won a default judgement against counterfeiter in the United States District Court for the Southern District of New York in a civil action against Global Medi Products, a South Korean company.
  • The Default Judgment against Global Medi Products was on numerous counts including tortious business interference, defamation, trademark infringement, and unfair competition.
  • Aquavit Pharmaceuticals, Inc. is a high-tech pharmaceutical company that provides a comprehensive range of innovative pharmaceutical, biotech and medical device technologies.
  • Aquavit Pharmaceuticals, Inc. focuses on personalized medicine to improve patients' health, maximize the efficiency of our medical community, and support the pharmacoeconomics of payers.

Aquavit Pharmaceuticals Unveils Its Platform Technology Addressing COVID-19 at 2020 BIO International Conference - Digital

Retrieved on: 
Monday, June 8, 2020
Viruses, Health, Coronaviridae, Zoonoses, Animal virology, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Aquavit, CoV, Pharmaceutical industry in China

NEW YORK, June 8, 2020 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. (Aquavit), a biotechnology company focused on the development of a first-of-its-kind microchannel drug delivery technology, is proud to announce its participation in the 2020 BIO International Convention which will take place for the first time in a fully digital format ("BIO Digital 2020").

Key Points: 
  • NEW YORK, June 8, 2020 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. (Aquavit), a biotechnology company focused on the development of a first-of-its-kind microchannel drug delivery technology, is proud to announce its participation in the 2020 BIO International Convention which will take place for the first time in a fully digital format ("BIO Digital 2020").
  • Earlier this year, Aquavit announced the filing of new patent applications for a new drug delivery platform and vaccine compositions for immunizing patients against the SARS-CoV-2 coronavirus.
  • The patent applications cover platform technologies directed to novel methods for immunizing patients against infectious diseases such as COVID-19 using microchannel delivery devices.
  • Our technology is self-administrable for any pandemic situations like the COVID-19 outbreak," says Sobin Chang, CEO of Aquavit at an interview with Backstage BIO 2020.

Police Crackdown of Pirating AQUAGOLD® fine touch™

Retrieved on: 
Sunday, March 17, 2019
Articles, Life sciences, Biotechnology, Pharmaceutical industry, Counterfeit consumer goods, Aquavit, Trademark, Food and Drug Administration, Pharmaceutical industry in India, Biopharmaceutical, KFDA, EUM

U-BioMed has been manufacturing and selling counterfeit products under the trademark of AQUAGOLD fine touch, owned by Aquavit Pharmaceuticals, Inc. and its Korean subsidiary, Aquavit Life Sciences, Inc.

Key Points: 
  • U-BioMed has been manufacturing and selling counterfeit products under the trademark of AQUAGOLD fine touch, owned by Aquavit Pharmaceuticals, Inc. and its Korean subsidiary, Aquavit Life Sciences, Inc.
  • Police requested that U-BioMed's CEO, Eum Nyun Shik, who also goes by the alias Corea Eum, appear at the police station earlier today.
  • Since the launch of AQUAGOLD fine touch with its official web site www.AQUAGOLDFINETOUCH.com , AQUAGOLD products have been adored by many celebrities and media outlets worldwide.
  • AQUAGOLD fine touch is an FDA registered, CE Marked, KFDA registered medical device intended to micro-inject valuable drugs or biologics into the skin.